139 related articles for article (PubMed ID: 33571514)
1. Saroglitazar, a novel dual PPAR-α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice.
Dharavath RN; Arora S; Kondepudi KK; Bishnoi M; Chopra K
Life Sci; 2021 Apr; 271():119191. PubMed ID: 33571514
[TBL] [Abstract][Full Text] [Related]
2. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
[TBL] [Abstract][Full Text] [Related]
3. High fat-low protein diet induces metabolic alterations and cognitive dysfunction in female rats.
Dharavath RN; Arora S; Bishnoi M; Kondepudi KK; Chopra K
Metab Brain Dis; 2019 Dec; 34(6):1531-1546. PubMed ID: 31313125
[TBL] [Abstract][Full Text] [Related]
4. The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin.
Makled MN; Sharawy MH; El-Awady MS
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1569-1576. PubMed ID: 31367862
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
Ezhilarasan D
Metabolism; 2024 Jun; 155():155912. PubMed ID: 38609038
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
7. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
8. Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy.
Joharapurkar A; Patel V; Kshirsagar S; Patel MS; Savsani H; Jain M
Eur J Pharmacol; 2021 May; 899():174032. PubMed ID: 33753107
[TBL] [Abstract][Full Text] [Related]
9. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
[TBL] [Abstract][Full Text] [Related]
10. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity.
Kamau F; Strijdom H; Mwangi P; Blackhurst D; Imperial E; Salie R
Vascul Pharmacol; 2019 Oct; 121():106577. PubMed ID: 31284000
[TBL] [Abstract][Full Text] [Related]
12. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
Sarkar S; Kumari D; Gupta SK; Sharma V; Mukhi S; Kamboj P; Sasibhushan V; Rai RK; Jatavallabhula SL; Mahajan D; Kumar Y; Kumar A; Dikshit M
Biomed Pharmacother; 2021 Dec; 144():112357. PubMed ID: 34794234
[TBL] [Abstract][Full Text] [Related]
13. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
[TBL] [Abstract][Full Text] [Related]
14. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
[TBL] [Abstract][Full Text] [Related]
15. Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.
Kalliora C; Kyriazis ID; Oka SI; Lieu MJ; Yue Y; Area-Gomez E; Pol CJ; Tian Y; Mizushima W; Chin A; Scerbo D; Schulze PC; Civelek M; Sadoshima J; Madesh M; Goldberg IJ; Drosatos K
JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393858
[TBL] [Abstract][Full Text] [Related]
16. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
[TBL] [Abstract][Full Text] [Related]
17. Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α.
Xie Z; Gao G; Wang H; Li E; Yuan Y; Xu J; Zhang Z; Wang P; Fu Y; Zeng H; Song J; Hölscher C; Chen H
Biomed Pharmacother; 2020 Jul; 127():110155. PubMed ID: 32413669
[TBL] [Abstract][Full Text] [Related]
18. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Chira EC; McMillen TS; Wang S; Haw A; O'Brien KD; Wight TN; Chait A
Atherosclerosis; 2007 Nov; 195(1):100-9. PubMed ID: 17214992
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
[TBL] [Abstract][Full Text] [Related]
20. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.
Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T
J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
